Updated hourlyHourly refreshTue, Oct 27, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Healthcare
WALTHAM, Mass., Sept. 25, 2026 -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 31,200 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on September 24, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).
Sep 25 · 20:15·GlobeNewswire
Finance · Healthcare
REDWOOD CITY, Calif., September 25, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the Company will report clinical data from the Phase 1 study evaluating prulacabtagene leucel (prula-cel) as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephriti
Sep 25 · 20:00·Business Wire
Biotech & pharma
If you purchased or acquired Capricor securities between December 17, 2025 and July 26, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.
Sep 25 · 17:24·GlobeNewswire
Healthcare · Biotech & pharma
First Hospital in the Country to Enroll Patients SPRINGFIELD, Mass., Sept. 25, 2026 -- Baystate Health announced today that it was selected to participate in a groundbreaking national clinical trial for Advanced Brain Aneurysm treatment and has enrolled the country's first...
Sep 25 · 17:00·PR Newswire
Finance · Healthcare
NEW YORK, Sept. 25, 2026 -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced preclinical data from studies evaluating SLS009 (tambiciclib), its highly selective cyclin-dependent kinases 9 (CDK9) inhibitor, in patient-derived organoid models of pancreatic ductal adenocarcinoma (PDAC). The data are being presented at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, being held September 25–28, 2026, in San Diego. The timing of this announcement reflects AACR’s embargo policy, under which the data presented at the conference were restricted from publication until 1:00 p.m. ET today.
Sep 25 · 17:00·GlobeNewswire
Biotech & pharma
MONTREAL, Sept. 25, 2026 -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 345 on the 2026 Report on Business magazine’s ranking of Canada’s Top Growing Companies.
Sep 25 · 13:55·GlobeNewswire
SaaS · Biotech & pharma
The agreement grants Novo a global exclusive license to Nanexa's proprietary PharmaShell® atomic layer deposition (ALD) drug delivery technology platform for certain therapeutic peptide drugs in indications including obesity, type 2 diabetes and other cardiometabolic diseases. The...
Sep 25 · 12:00·PR Newswire
AI · Healthcare
SHANGHAI, Sept. 25, 2026 -- Nutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announced FDA IND clearance for NTS231, a covalent allosteric molecular glue degrader of NRF2, to...
Sep 25 · 12:00·PR Newswire
Healthcare · Biotech & pharma
LONDON and PHILADELPHIA, Sept. 25, 2026 -- Avacta Therapeutics (AIM: AVCT, the "Company", "Avacta"), a life sciences company developing innovative, targeted oncology drugs, today announces the presentation of the FOCUS-01 trial design and preclinical data highlighting the potential of AVA6103 (FAP-Exd) in pancreatic ductal adenocarcinoma (PDAC). FOCUS-01 is the Phase 1 trial of AVA6103, the Company's first Next-Generation pre|CISION® peptide-drug conjugate (PDC) and is being presented at the American Association for Cancer Research ("AACR") Conference on Pancreatic Cancer in San Diego, California, held between 25-28 September 2026.
Sep 25 · 06:00·GlobeNewswire
Biotech & pharma
HONG KONG, Sept. 25, 2026 -- The ICAC, the Hong Kong International Academy Against Corruption, the United Nations Office on Drugs and Crime (UNODC) and the Global Operational Network of Anti-Corruption Law Enforcement Authorities (GlobE Network) jointly organised the...
Sep 25 · 04:57·PR Newswire
Finance · Biotech & pharma
New York, New York--(September 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
Sep 25 · 02:26·Newsfile
Biotech & pharma
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
Sep 24 · 23:33·GlobeNewswire